References
- European Medicines Agency. Biosimilar medicines. 2017. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/general/general_content_001832.jsp&mid=WC0b01ac0580bb8fda [Last accessed 18 October 2017]
- European Medicines Agency. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human follicle stimulating hormone (r-hFSH). 2011. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/03/WC500139624.pdf [Last accessed 19 October 2017]
- Sunkara SK, Rittenberg V, Raine-Fenning N, et al. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod 2011;26:1768–74
- European Medicines Agency. EPAR summary for the public: GONAL-f 2010. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000071/WC500023742.pdf [Last accessed 12 February 2018]
- Teva Pharma BV. Follitropin alfa (Ovaleap) 300IU/0.5ml, 450IU/0.75ml, 900IU/1.5ml Solution for Injection. 2017. Available at: https://www.medicines.org.uk/emc/medicine/33917 [Last accessed 18 October 2017]
- Merck. GONAL-f 450 IU (33 mcg) pen. 2017. Available at: https://www.medicines.org.uk/emc/medicine/14384 [Last accessed 18 October 2017]
- Rettenbacher M, Andersen AN, Garcia-Velasco JA, et al. A multi-centre phase 3 study comparing efficacy and safety of Bemfola versus Gonal-f in women undergoing ovarian stimulation for IVF. Reprod Biomed Online 2015;30:504-13
- European Medicines Agency. Ovaleap: follitropin alfa. 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002608/WC500152909.pdf [Last accessed 18 October 2017]
- Strowitzki T, Kuczynski W, Mueller A, et al. Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART). Reprod Biol Endocrinol 2016;14:1
- European Medicines Agency. Assessment Report: Ovaleap. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002608/WC500152908.pdf [Last accessed 12 February 2018]
- Lauer-Fischer GmbH. Webapo InfoSystem. Germany; 2016
- EBM Online Catalogue. Available at: http://www.kbv.de/html/online-ebm.php [Last accessed 12 February 2018]
- Institut für das Entgeltsystem im Krankenhaus GmbH. G-DRG-Fallpauschalen-Katalog 2017. 2017. Available at: http://www.g-drg.de/G-DRG-System_2017/Fallpauschalen-Katalog2/Fallpauschalen-Katalog_2017 [Last accessed 1 June 2017]
- GKV-Spitzenverband. Verband der Privaten Krankenversicherung e.V. and Deutsche Krankenhausgesellschaft e.V., Vereinbarung gemäß § 10 Abs. 9 KHEntgG für den Vereinbarungszeitraum 2017. Available at: http://www.dkgev.de/media/file/27711.Vereinbarung_Bundesbasisfallwert_2017.pdf [Last accessed 1 June 2017]
- Ministero della Salute. 2014. Available at: http://www.salute.gov.it/ [Last accessed 12 February 2018]
- Agenzia Italiana del Farmaco. Gazzetta Ufficiale Elenco Atti dell'emittente Agenzia Italiana del Farmaco. Available at: http://www.gazzettaufficiale.it [Last accessed 12 February 2018]
- MSSSI. Registro de Altas de los Hospitales Generales del Sistema Nacional de Salud. CMBD. Norma Estatal. Available at: https://www.msssi.gob.es/estadEstudios/estadisticas/cmbdhome.htm [Last accessed 1 June 2017]
- Gisbert R, Brosa M. eSalud Sanitary costs database. 2016. Available at: http://www.oblikue.com/en/index.htm [Last accessed 12 February 2018]
- Gizzo S, Garcia-Velasco JA, Heiman F, et al. A cost-effectiveness evaluation comparing originator follitropin alfa to the biosimilar for the treatment of infertility. Int J Womens Health 2016;8:683-9